RxSight (RXST) Cash & Equivalents Growth (1y) (2021 - 2026)
RxSight (RXST) Cash & Equivalents Growth (1y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.57 Bn | 193.97 Bn | 7.27 Bn | -26.57% |
| 2 | Stryker | 127.25 Bn | 123.77 Bn | 4.50 Bn | 42.78% |
| 3 | Medtronic | 118.81 Bn | 109.59 Bn | 6.41 Bn | -12.13% |
| 4 | Boston Scientific | 73.35 Bn | 72.81 Bn | 3.85 Bn | 0.94% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -11.19% |
| 6 | Dexcom | 34.28 Bn | 32.34 Bn | 830.00 Mn | -4.66% |
| 7 | GE HealthCare Technologies | 33.75 Bn | 31.64 Bn | 2.18 Bn | -44.03% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 19.49% |
| 9 | Steris | 23.03 Bn | 22.55 Bn | 684.20 Mn | 72.43% |
| 10 | RxSight | 250.19 Mn | -154.06 Mn | - | -8.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.22% |
| Mar 31, 2026 | -4.97% |
| Dec 31, 2025 | 1,265.38% |
| Sep 30, 2025 | 1,260.65% |
| Jun 30, 2025 | -2.44% |
| Mar 31, 2025 | 95.14% |
| Dec 31, 2024 | -86.87% |
| Sep 30, 2024 | -87.32% |
| Jun 30, 2024 | 58.53% |
| Mar 31, 2024 | -20.77% |
| Dec 31, 2023 | 20.23% |
| Sep 30, 2023 | 22.19% |
| Jun 30, 2023 | 15.41% |
| Mar 31, 2023 | 514.59% |
| Dec 31, 2022 | -33.58% |
| Sep 30, 2022 | -34.72% |
| Jun 30, 2022 | 110.00% |
| Dec 31, 2021 | 1,038.35% |